作者
HL Wong, AM Rauth, R Bendayan, XY Wu
发表日期
2006
期刊
J Control Release
卷号
116
期号
3
页码范围
275-284
简介
Multidrug-resistant (MDR) cancer may be treated using combinations of encapsulated cytotoxic drugs and chemosensitizers. To optimize for the effectiveness of this combinational approach, novel polymer-lipid hybrid nanoparticle (PLN) formulations capable of delivering a cytotoxic drug, doxorubicin (Dox), a chemosensitizer, GG918, or their combination were prepared. Both acute and long-term anticancer activities of various combinations of Dox and GG918 in solution or PLN form were evaluated in a human MDR breast cancer cell line (MDA435/LCC6/MDR1) using trypan blue exclusion and clonogenic assays. Cellular Dox uptake and drug distribution within the cells were determined by fluoremetry and fluorescence microscopy. The results showed that the encapsulation efficiencies of Dox and GG918 in PLN were up to 89% and were not compromised by co-encapsulation of the two agents. Of various …
引用总数
学术搜索中的文章
HL Wong, R Bendayan, AM Rauth, XY Wu - Journal of controlled release, 2006
HL Wong, AM Rauth, R Bendayan, XY Wu - J Control Release, 2006